Analyst
Truist
Equibles does not estimate personal net worth.
Dannielle Brill is recorded as Analyst at Truist. Dannielle Brill has spoken on 5 earnings calls across 4 companies, most recently for INSMED Inc on August 6, 2026. Those appearances were for Neurocrine Biosciences Inc (NBIX), INSMED Inc (INSM), Harmony Biosciences Holdings, Inc. (HRMY) and BridgeBio Pharma, Inc. (BBIO). The companies whose calls Dannielle Brill spoke on are classified in the Healthcare sector.
“I did have a follow-up on the peak sales assumption. So you noted the high-level rationale, but I'm curious if you could kind of break down what specific assumptions changed to move the needle from $5 billion to $7 billion at peak.”
“And what should we expect in terms of discontinuity? Thank you.”
“So you guys highlighted really strong growth in your prescriber base, but can you comment on trends in repeat prescribing? I think you noted roughly two-thirds of prescribers have only written a single prescription on your prior call.”
“Neil, I believe you mentioned in your prepared remarks that there were 6,100 new patient starts across the class in the quarter. If I recall correctly, This represents a pretty meaningful step up from prior quarters where I think it was more in the 4,000 new patients range.”
“So I know we talked a lot about general barriers to prescribing chronicity and mentioned a few times that two-thirds of your prescribers have only written a single prescription.”
Truist
Analyst
Transcript header (unverified)
Drug Manufacturers - Specialty & Generic · Healthcare
INSM
Biotechnology · Healthcare
